Ariad Pharmaceuticals, Inc. (ARIA) Provides Update on Important Progress Being Made in R&D and Commercial Initiatives
4/4/2013 11:55:15 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today provided an update on its progress over the past several weeks with both the commercial launch of Iclusig™ (ponatinib) in the United States and the clinical development programs for Iclusig and AP26113. We are providing this update to further clarify our recent news announcements and to respond to investor questions.
comments powered by